1-[4-cyano-2-(2-furanyl)-5-oxazolyl]-4-piperidinecarboxamide

1-[4-cyano-2-(2-furanyl)-5-oxazolyl]-4-piperidinecarboxamide, also known as **PF-06651600**, is a **potent and selective inhibitor of the protein-tyrosine phosphatase 1B (PTP1B)**.

**PTP1B** is an enzyme that plays a crucial role in **regulating insulin signaling**. By dephosphorylating the insulin receptor, PTP1B negatively regulates insulin signaling, leading to **insulin resistance** and potentially **type 2 diabetes**.

**PF-06651600** has been extensively studied as a potential **therapeutic agent for the treatment of type 2 diabetes**. It has shown promising results in preclinical studies by:

* **Improving insulin sensitivity:** PF-06651600 inhibits PTP1B, leading to enhanced insulin signaling and improved glucose uptake by cells.
* **Lowering blood glucose levels:** Studies in animal models have shown that PF-06651600 can effectively lower blood glucose levels.
* **Demonstrating good pharmacological properties:** PF-06651600 has shown good pharmacokinetic properties, including good oral bioavailability and a suitable half-life.

**However, PF-06651600 did not progress to clinical trials.** Despite its promising preclinical results, there were concerns about potential off-target effects and toxicity.

**Research Significance:**

* **Understanding PTP1B function:** PF-06651600 played a crucial role in understanding the role of PTP1B in insulin signaling and diabetes development.
* **Developing new diabetes therapies:** The research on PF-06651600 has provided valuable insights into the potential of PTP1B inhibitors for treating type 2 diabetes.
* **Exploring new drug targets:** PF-06651600 and its development process have inspired the development of other PTP1B inhibitors and potential therapeutic targets for metabolic disorders.

While PF-06651600 itself did not reach clinical trials, its research has significantly contributed to the understanding of PTP1B and its role in diabetes. This knowledge continues to be valuable for developing new and improved therapeutic strategies for the management of type 2 diabetes and other metabolic disorders.